

CLAIMS

1. ~~An anti-PD-1 antibody~~ Nivolumab for use in a method of treating melanoma in combination with ~~an anti-CTLA-4 antibody~~ ipilimumab, ~~wherein the anti-PD-1 antibody is nivolumab;~~

5 wherein the method comprises:

(i) an induction dosing schedule comprising administration of nivolumab and ~~the anti-CTLA-4 antibody~~ ipilimumab at a dosing frequency of once every 3 weeks for 4 doses, followed by administration of nivolumab alone at a dosing frequency of once every 3 weeks for 4 doses; followed by

10 (ii) a maintenance dosing schedule comprising administration of nivolumab and ipilimumab ~~the anti-CTLA-4 antibody~~ at a dosing frequency of once every 2 to 12 weeks for 8 doses, and

15 wherein nivolumab and ipilimumab ~~the anti-CTLA-4 antibody~~ are to be administered at dosages of: 1 mg/kg of nivolumab and 3 mg/kg of ipilimumab ~~the anti-CTLA-4 antibody~~.

2. ~~The anti-PD-1 antibody~~ Nivolumab for use of claim 1, wherein the cancer is an advanced, recurring, metastatic, and/or refractory cancer.

3. ~~The anti-PD-1 antibody~~ Nivolumab for use of claim 1 or 2, wherein the treatment
20 is further combined with one ~~of~~ or more of chemotherapy, radiation, surgery, hormone deprivation, angiogenesis inhibitors, and an anti-PD-L1 antibody or antigen-binding portion thereof.

4. ~~The anti-PD-1 antibody for use of any one of claims 1 to 3, wherein the anti-CTLA-4 antibody is ipilimumab.~~

25 ~~54.~~ 54. ~~The anti-PD-1 antibody~~ Nivolumab for use of any one of claims 1 to ~~43~~ 43, further comprising assessing the proportion of cells that express PD-L1 on the cell surface in a test tissue sample obtained from the subject.

30 ~~65.~~ 65. ~~The anti-PD-1 antibody~~ Nivolumab for use of claim ~~45~~ 45, wherein the proportion of cells that express PD-L1 on the cell surface is determined by immunohistochemistry using an anti-PD-L1 antibody.

76. The anti-PD-1 antibody Nivolumab for use of claim 65, wherein the anti-PD-L1 antibody comprises the CDR1, CDR2, and CDR3 regions in a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 35, and the CDR1, CDR2 and CDR3 regions in a light chain variable region
5 comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 36.

87. The anti-PD-1 antibody Nivolumab for use of claim 65 or 76, wherein the anti-PD-L1 antibody comprises a heavy chain variable region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 35, and a light chain variable
10 region comprising consecutively linked amino acids having the sequence set forth in SEQ ID NO: 36.